Sector News

Drug maker Sobi eyes sale of Partner Products unit

February 6, 2017
Life sciences

Swedish drug maker Swedish Orphan Biovitrum (Sobi) said on Friday it was in talks with a private equity firm regarding a possible sale of its Partner Products business area.

“We have noted specific information in the market regarding a possible sale of Sobi Partner Products. We confirm that we are in discussions which may or may not lead to an agreement,” Sobi CEO Geoffrey McDonough said in a statement.

Sobi, which has Investor AB as its biggest owner, said the talks did not include drugs Kineret and Orfadin.

Partner Products had sales of 617 million Swedish crowns ($70 million) in the January-September period 2016, while Sobi’s total sales were 3.9 billion crowns.

Sobi rose 2.1 percent at 1402 GMT after an earlier trading halt was lifted. The share was flat before the trading halt.

By Johannes Hellstrom

Source: Reuters

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach